ArticlePLOS global public health2025
Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma, characterized by chronic and progressive degeneration of retinal ganglion cells leading to a gradual decline in the visual field, poses a significant challenge in eye care delivery. Optometrists play a vital role in detecting and managing glaucoma. This study aims to determine how Ghanaian optometrists manage ocular adverse reactions (OADRs) in patients using antiglaucoma medications. A cross-sectional survey was conducted among 139 licensed optometrists using a pre-tested, semi-structured questionnaire. Data collected included socio-demographic characteristics, reported adverse reactions, and awareness of reporting or management protocols. Descriptive and inferential statistics were performed using SPSS version 25.0. Participants had a mean age of 31.6 ± 5.5 years and an average practice experience of 5.6 ± 4.5 years. Most respondents were female (71.2%), with 36.7% practicing in Greater Accra and 32.0% in private facilities. Nearly all participants (92.8%) reported encountering OADRs to AGMs. The most common symptoms were red eyes (36.0%), stinging (26.1%), burning sensation (25.4%), and itching (8.8%), while clinical signs included conjunctival hyperemia (45.5%), tear film deficiency (26.0%), and iris pigmentation changes (9.8%). Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. Optometrists primarily managed cases by switching to alternative medications (41.0%) or adjusting dosage and frequency (9.7%). However, 77.7% reported having no knowledge of existing protocols, and confidence in managing OADRs was moderately low (mean = 2.67 ± 0.49 on a 5-point scale). No significant association was found between OADR reporting and either age (p = 0.616) or years of practice (p = 0.974). These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.